Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Open accessThe DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages. However, colorectal cancer is not a single type of tumor; its pathogenesis depends on the anatomical location of the tumor and differs between right side and left side of the colon. Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology. Therapy responses are totally different between these tumor entities. Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load. For the development of effective therapy regimes and better treatment options, it is essential to evaluate right-sided and left-sided tumors as separate entities, and design the therapy regime considering the differences between these tumors. Gastroenterol Res. 2018;11(4):264-273 doi: https://doi.org/10.14740/gr1062w
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Right-sided tumors more commonly exhibit DNA mismatch repair deficiencies, while left-sided tumors often have mutations in KRAS, APC, PIK3CA, and p53 [30].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“highly use these regulators as an anti-tumor immune response [82, 83].”
BackgroundA genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Metastatic melanoma is one of the tumors with high immunogenic load and melanoma patients are highly benefiting from anti-CTLA-4 and anti-PD-1 therapies [87, 88].”
BackgroundGenetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 4×
“Presence of T cells in these tumors is associated with better prognosis and less frequent metastasis [12, 13, 24].”
BackgroundInfluentialImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Interestingly, tumor infiltrating lymphocytes express high level of PD-L1, which is thought to be a result of chronic stimulation because of the neoantigen load [86].”
Background
Cited by
Items 501–581 of 581
Zhu, S., Tu, J., Pei, W., Zheng, Z., 毕建军, & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630281
Zhu, S., Tu, J., Pei, W., Zheng, Z., 毕建军, & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630272
Zhu, S., Tu, J., Pei, W., Zheng, Z., 毕建军, & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630290
Zhu, S., Tu, J., Pei, W., Zheng, Z., 毕建军, & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630278
Intra-clonal gene expression heterogeneity in human colorectal cancer
Kasem, M. H. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00034798
Zhu, S., Tu, J., Pei, W., Zheng, Z., 毕建军, & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630287
Zhu, S., Tu, J., Pei, W., Zheng, Z., 毕建军, & Feng, Q. (2023) · Figshare · doi:10.6084/m9.figshare.24417590
Zhu, S., Tu, J., Pei, W., Zheng, Z., 毕建军, & Feng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630305
Yan, X., Wang, K., Bao, Q., Wang, H.-W., 金克敏, Wang, J.-Y., & Xing, B.-C. (2021) · Figshare · doi:10.6084/m9.figshare.14880872
Impact of commonly prescribed drugs on the risk of colorectal cancer
Liu, Q. (2023) · Open Archive (Karolinska Institutet)
Galindo-Regal, L. (2023) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
Personalized medicine in cancer: liquid biopsy-based biomarkers
Toledano‐Fonseca, M. (2021) · Universidad de Córdoba Insitutional Repository (Universidad de Córdoba) · Cited by 1
Silveira, J. D. O. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Ćorić, N., Banjari, I., Marijanović, I., Vazdar, L., & Tomaš, I. (2024) · University of Zagreb University Computing Centre (SRCE)
Campos Gudiño, R. (2023) · Mspace (University of Manitoba)
Expression of β-catenin, Ki67 and stroma percentage in colorectal cancer
Suanno, C. (2021) · Nottingham ePrints (University of Nottingham)
Carcinoma colorrectal e metástases hepáticas - o efeito do microambiente
Oliveira, R. P. C. M. D. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/5y07-6z16
Analysis of CCR5 expression in patients with colon cancer using immunohistochemical method
Slezeviciene, R. (2023) · Jönköping University Publications (Jönköping University)
Tayyab, M., Minkkinen, M. M. E., Stenvall, C.-G. A., Polari, L., Nielsen, V., Shah, Y. M., & Toivola, D. M. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101716
Santos, I., Liberal, J. M. T., Teixeira, P., Martins, D., & Mendes, F. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.070281
“Right-sided tumors are enriched in MSI-high and BRAF mutations, frequently display hyperme-thylation phenotypes, and show stronger immune infiltration [198].”
Melo, N. D. O. R. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Khan, A. A., Hasan, F., Marsool, M. D. M., Uzair, M., Maryam, K. U. E., Babar, M. U., Talha, M., Imran, H., Bakhsh, R. M. M., Zulfiqar, K., et al. (2026) · Clinical Endoscopy · doi:10.5946/ce.2025.163
“56 The EV device's capacity to evert the intestinal folds and improve vision is very beneficial.”
Guzman, P., Castillo, K., Rosales, M. Y., Alfaro, A., Breedy, G. M., Castillo, E., & Leon, A. (2026) · Journal of Cancer Therapy · doi:10.4236/jct.2026.172011
Sakshaug, B. C., Haukaas, T. H., Folkesson, E., Ringers, C., Bwanika, H. C., Bergstrøm, I. A., Sigfúsdóttir, M. S., Trøen, H. H., Sperstad, S. B., Stornes, T., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0473
“It is plausible that the aggres-siveness of a tumor—indicated by higher clinical stage—and disparities between right-and left-sided tumors (37) affect PDT culture success rate, which warrants further investigation.”
Stahl, A., Büringer, K., Missios, P., Hoffmann, T., Mattern, S., Singer, S., Schäfer-Ruoff, F., MALEK, N. P., Schenke‐Layland, K., Bitzer, M., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01304-5
“Inclinicalpractice, right-and left-sided colon carcinomas are differentiated 56,57 as subgroups with strongly different molecular characteristics and treatment responses.”
Emergency surgery for malignant large bowel obstruction: Assessing management options and outcomes
Moyana, T. N. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v18.i2.113867
Quantitative Prognostic Stromal Assessment of Colorectal Cancer using Polarized Light Microscopy
Lad, J. (2023) · TSpace (University of Toronto)
Damayanthi, T. (2026) · medRxiv · doi:10.64898/2026.03.03.26347325
Wildan, A., Christabel, E. V., Rinaldi, I., Abdullah, M., & Makmun, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1781435
Weng, J., Wang, J., Tao, Z., Wu, T., Diao, K., Wang, J., Wang, N., Ye, Z., Zhang, R., Shen, J., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01354-9
“Aneuploidy 17,18 and right-sided CRC 19 have been reported to be associated with poor chemotherapy response; we fi nd that aneuploidy and primary tumor location had no effects in the prediction of oxaliplatin-based chemotherapy clinical response (Fig.”
Differential immunoreactivity of alpha-smooth muscle actin in the mouse colon
Ishizaki, Y., Onizawa, M., Abe, N., Murakami, M., Mochimaru, T., Sakuma, C., Watahiki, Y., Nemoto, D., Kawashima, K., Uemura, T., et al. (2026) · Anatomical Science International · doi:10.1007/s12565-026-00924-y
A differential single-cell transcriptome atlas of left-sided and right-sided colorectal cancer
Zhao, C., Zhou, W., Zeng, G., Huang, Y., Shi, C., Ma, H., Li, Y., Lv, J., Liang, X., & Fang, S. (2026) · Discover Oncology · doi:10.1007/s12672-026-04789-5
Saleh, M. A., Iramu, R., Kazema, R., & Fundikira, L. S. (2026) · Surgical Oncology · doi:10.1016/j.suronc.2026.102406
Bartulić, A., Marušić, R., Centner, M. G., Centner, H., Schönberger, E., Rimac, D. S., Dukić, D., Đukić, G., Flam, J., Mihić, D., et al. (2026) · Southeastern European medical journal · doi:10.26332/dpcz2937
Budianto, A., Sugiharto, S., & Fildahlina, D. (2026) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.25.05954-6
Закирович, А. А., Vesnushkin, G. M., Александрович, М. К., & Kondrashkin, A. A. (2026) · Medicine and Biotechnology · doi:10.15507/3034-6231.002.202601.071-087
Yadav, P., Chakraborty, R., Rana, K., Jha, S. K., Gupta, S. K., Pandey, N., Khan, A., Mehta, D., Jain, D., Yadav, M., et al. (2026) · Chemistry of Materials · doi:10.1021/acs.chemmater.5c01499
Balogoun, R. (2019) · theses.fr (ABES) · doi:10.70675/b078c676z06b0z4093za0f0zf4b5ac1484fb
Identification of new biomarkers for colorectal cancers
Hasanova, R. (2019) · theses.fr (ABES) · doi:10.70675/38dbe0adza892z41d3za889zbee31c0eb152
Management of Hepatic Metastases from Colorectal Cancer
Sheng, M., Gade, T. P. F., & Nadolski, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-03935-4_29
Prognostic Significance of Histomorphological Features beyond TNM Staging in Colon Cancer Survival
Pradhan, S., Pani, K. C., Navas, M., Satpathy, B. B., Devi, P., Goyal, J., & Dash, S. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00145
Devall, M. A. M., Taha, H. M., Chen, M., Eaton, S. D., Sun, X., Venkatesh, S., Ramirez, A., Habib, F. Z., Ali, M. I., Cooper, G. S., et al. (2026) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-25-1685
Oreiby, M. A.-E., Said, W. M., Gad, O. A. E.-F., & Hussein, F. Z. (2026) · Tanta Medical Journal · doi:10.4103/tmj.tmj_38_24
Xu, H., Luo, R., Chen, W., Sun, Q., Chen, H., Liu, K., & Hou, J. (2026) · Molecular Carcinogenesis · doi:10.1002/mc.70123
“Notably, LSCC more frequently progresses via the chromosomal instability (CIN) pathway, and TP53 mutation is a core event in the CIN pathway [25]—this explains the enrichment of TP53 mutations in LSCC.”
Pediatric Lynch syndrome: Clinical, genotypic, and left‐sided patterns of colorectal cancer
Phen, C., Rojas, I., Friesen, H. J., Swaggart, K., Flahive, C. B., MacFarland, S. P., & Attard, T. M. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70445
Djaballah-Ider, F. Z., Gouaref, I., Seghirate, A., Touil–Boukoffa, C., & Galleze, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093709
“Indeed, right-and left-sided colorectal cancers differ in their embryological origin, molecular profile, and tumor microenvironment [52].”
Comparative assessment of the mucosa of index segments of the colon in colorectal cancer
Короткевич, А. Г., Titov, S. E., Zhilina, N. M., Сергеевич, Д. П., Бондарев, О. И., Veryaskina, Y. A., & Маринич, Я. Я. (2026) · Клиническая эндоскопия. · doi:10.31146/2415-7813-endo-68-1-31-40
Singh, D. K. D. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.20s.75
“Due to their rapid progression and association with microsatellite instability, these lesions require careful endoscopic surveillance and timely resection to prevent malignant transformation [7].”
Agrawal, R., & Choi, A. J. (2026) · Cancers · doi:10.3390/cancers18091450
“This is likely related to later discovery of more proximal disease leading to more advanced malignancy at diagnosis and to a generally worse response to systemic chemotherapy, among other factors [38].”
Clinical Analysis of Colorectal Cancer Among Sample of Iraqi Patients Between 2018 and 2023
alkareem, F. O. A., & Mohamad, B. J. (2026) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_1435_23
Clinical Impact of Preoperative Sarcopenia on the Outcome of Patients With Right-Sided Colon Cancer
Erginöz, E., Güldağ, M. A., Nakashidze, M., Sak, K., Ergün, S., Uludağ, S. S., Demiryas, S., Zengin, K., Batur, Ş., Kepil, N., et al. (2026) · The American Surgeon · doi:10.1177/00031348261450572
Wanitsuwan, W., Kanjanapradit, K., Jearanai, S., Suphasynth, Y., Supaattagorn, P., Vijasika, S., Wanram, S., Ngamphiw, C., Nakhonsri, V., Tongsima, S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348867
Histopathological characteristics of screen-detected colorectal cancers
Ward, C., O’Reilly, M., Guerin, C., Buckley, M., Cotter, M. B., Cullen, G. J., Doherty, G., Gibbons, D., Hamed, M., Hanly, A. M., et al. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04429-x
Martins, M. P. R., Andrade, R. L. D. F., Delfino, P. H. V., do Amaral, L. R., Braga, L. D. C., & Martins‐Chaves, R. R. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03468-3
“RCC is frequently associated with BRAF mutations and high-frequency microsatellite instability resulting from defective DNA mismatch repair, leading to widespread genomic alterations [27].”
Sun, C. J., Liu, L., Lees, E. H., Billstein, L., Zou, Y., Fickel, A. K., Yan, Y., Wang, Y., Vinh, T., Travers, P., et al. (2026) · Cancers · doi:10.3390/cancers18111768
Young onset rectal cancer (YORC): a descriptive tertiary center analysis
Schraepen, C., Rasschaert, G., Maerten, P., Bislenghi, G., Hertogh, G. D., Debrun, L., Dresen, R. C., Leclercq, P., Sagaert, X., Tejpar, S., et al. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.111925
Uncovering long non-coding RNA regulators of colorectal cancer progression
Kufrin, V. (2026) · Qucosa (Saxon State and University Library Dresden)
Gerber, N. (2026) · Mspace (University of Manitoba)
Toledano‐Fonseca, M., DomÃnguez, I. D. L. F., Ortiz‐Morales, M. J., Cano-Ramírez, P., Pulido, G., Cano‐Osuna, M. T., García‐Ortiz, M. V., Gómez‐España, M. A., Rodríguez‐Ariza, A., & Aranda, E. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00856-3
“Right-sided and left-sided CRC differ in their metastatic pattern: right-side tumours more commonly metastasize to the peri-toneum, while left-sided CRC tends to metastasize to the liver and lungs [7, 8].”
Salhi, I., Maqboul, H., Jallad, F., Jaradat, H., Bannoura, S., El-Krunz, D., Karmi, B., & Salah, Z. (2026) · Research Square · doi:10.21203/rs.3.rs-9741043/v1
Tahiya, E. C. I., Lusikooy, R. E., Patellongi, I., Warsinggih, W., Uwuratuw, J. A., Syarifuddin, E., Labeda, I., Sampetoding, S., Kusuma, M. I., & Faruk, M. (2026) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2026.27.6.2269
“Although tumor biology is often influenced by histologic differentiation and anatomical site, therapeutic response to fluoropyrimidine-based regimens is primarily governed by molecular determinants rather than demographic or morphological factors [27].”
Immune-epithelial crosstalk governs immune checkpoint inhibitor efficacy in colorectal cancer
Lee, S. L., Bateman, A. C., Ashton‐Key, M., Primrose, J. N., Mirnezami, A., Al‐Shamkhani, A., & Thirdborough, S. M. (2026) · iScience · doi:10.1016/j.isci.2026.116544
Abrahão, A. B. K., Felismino, T. C., & Kerr, D. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01517-8
Solak, H. C., Mert, N., Leblebici, A., Işık, Z., Ellidokuz, E., & Mert-Ozupek, N. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351228
Self-citationLim, M., & Morris, V. K. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.07.003
Morais, A. M., de Alcântara, P. S. M., de Jesus, J. D. C. R., Andrade, A. M., Seelaender, M. C. L., & Otoch, J. P. (2026) · Frontiers in Surgery · doi:10.3389/fsurg.2026.1809373
Hálková, T., Pauerova, L. H., Blechová, K., Benešová, T., Grega, T., Brodyuk, N., Traboulsi, E., Hejcmanová, K., Ngo, O., Bureš, J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156547
Xu, G., Sun, X., Jiang, J., Jin, S. M., Li, L., Cheng, H., Zhu, Y., & Liu, H. (2026) · JMIR Cancer · doi:10.2196/101162
Song, M., Wu, F., Heng, Y., Nie, T., Liu, Z., Xu, J., Wu, X., Zhi, X., Zhang, W., Yang, Z., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1910628
Barbu, L. A., Mogoantă, S. Ş., Cojan, T. Ș. Ț., Mărgăritescu, N.-D., Mirea, C. S., Marinaş, M. C., & Vasile, L. (2026) · Life · doi:10.3390/life16091507
“Emerging evidence also indicates substantial spatial variation in the gut microbiota along the col-orectum, potentially influencing local inflammation, immune–tumor interactions, and tumor progression [26,28,29].”
Mutational Profile of Primary Tumors in Patients with Brain Metastases from Colorectal Cancer
Халафян, Д. А., Bekyashev, A. К., Строганова, А. М., Рогожин, Д. В., Козлов, Н. А., Насхлеташвили, Д. Р., Mitrofanov, A. A., Александрович, А. В., Sufianov, R. A., Abdulaeva, R. S., et al. (2026) · Voprosy Onkologii · doi:10.37469/0507-3758-2026-72-4-2635
“Получен-ные данные подтверждают гипотезу о том, что левосторонняя локализация, ассоциированная с хромосомной нестабильностью (CIN) и актива-цией EGFR-зависимых путей [19, 20], создает более благоприятный фон для пульмонального и церебрального метастазирования [21].”
AGRAWAL, S., ROY, S., NAYAK, M., & Choudhary, A. (2026) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2026v18i5.10002
Dong, W.-H., Ling, X., Chen, X.-D., Qian, J.-P., Jin, Y., & Gu, Y.-J. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.123187
Safi, R. A. A. R. A. S. A., Alhzamat, S. A. H., Fawzi, M., & Jabbar, S. (2026) · Medical Science Journal for Advance Research
Gaghana, L., Miskad, U. A., Cangara, M. H., Zainuddin, A. A., Mardiati, Arsyadi, G., & Wahid, S. (2022) · International Journal of Sciences: Basic and Applied Research
Wheler, J., Troelsen, F. S., Vágó, E., Horváth–Puhó, E., van Es, N., Moik, F., Ay, C., & Sørensen, H. T. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.09.040
Funktionelle Analyse der B-Plexine in intestinalen Tumorstammzellen
Hillert, N. (2026) · open_UMR Marburg DSpace 10.0 (Philipps-Universität Marburg) · doi:10.17192/openumr/1142
Халафян, Д. А., Хасьянович, Б. А., Строганова, А. М., Rogozhin, D. V., Козлов, Н. А., Насхлеташвили, Д. Р., Mitrofanov, A. A., Александрович, А. В., Sufianov, R. A., Шамильевна, А. Р., et al. (n.d.) · CyberLeninK (CyberLeninka)
Colorectal Cancer Demographics in Atlantans of Black Ancestry: A Single-Institution Study
Corbin, S., Cawich, S. O., Johnson, S. M., Fletcher, D., Montaque, T., Giffith, S., Doyle, A., & Chase, C. (2026) · Journal of Surgical Research · doi:10.1016/j.jss.2026.09.031
Origins and heterogeneity of colorectal cancer
Sphyris, N., Nasreddin, N., Leedham, S. J., & Sansom, O. J. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00988-y
Metadata
- Authors
- Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y.
- Affiliations
- Dokuz Eylül University (TR)
- ORCID
- Acar, Emine
- Venue
- Gastroenterology Research
- Publisher
- Elmer Press, Inc.
- Published
- 2018
- Volume
- 11
- Issue
- 4
- Pages
- 264-273
- ISSN
- 1918-2805 (ISSN-L)
- 1918-2813
- PMC
- PMC6089587
- OpenAlex
- W2887365295
- Cited by
- 553
- References
- 113
- Citations by year
- 2026: 62 · 2025: 59 · 2024: 117 · 2023: 76 · 2022: 66 · 2021: 90 · 2020: 56 · 2019: 25 · 2018: 2
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Gastroenterology Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- left-sided colorectal cancer, right-sided colorectal cancer, tumor location, mismatch repair deficiency, chromosomal instability, KRAS mutation, APC mutation, PIK3CA mutation, TP53 mutation, adjuvant chemotherapy, 5-fluorouracil, anti-EGFR therapy, immunotherapy, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.